Livedoid vasculopathy and high levels of lipoprotein (a)

Response to danazol

Paulo Ricardo Criado, Danielle Priscilia De Souza Espineli, Neusayuriko Sakai Valentef, Afsaneh Alavi, Robert Kirsner

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Livedoid vasculopathy (LV) is a thrombo occlusive disorder presenting with recurrent painful ulcers of lower extremities. Association of LV with increased level of lipoprotein (a) (LP(a)), a risk factor for cardiovascular disease, has been reported. Danazol has been used with success in the management of LV, but none of the previous studies looked at the correlation between response to the treatment and level of LP(a). The aim of this study was to demonstrate the efficacy of low-dose danazol in the treatment of LV and its effects on LP(a). We present four cases with LV who were successfully treated with low-dose danazol, assessing the clinical characteristics and laboratory tests including the level of LP(a). The average age of the patients was 45 years and the mean duration of the disease was 19 years. The treatment regime of danazol 200 mg daily led to complete healing of ulcers and reduction in pain and a 70% (ranging from 52 to 87%) reduction in the level of LP(a). The limitation of this study is "small sample size." In our patients with LV, low-dose danazol led to clinical improvement along with significant reduction in the level of LP(a).

Original languageEnglish (US)
Pages (from-to)248-253
Number of pages6
JournalDermatologic Therapy
Volume28
Issue number4
DOIs
StatePublished - Jul 1 2015

Fingerprint

Danazol
Lipoprotein(a)
Ulcer
Sample Size
Lower Extremity
Cardiovascular Diseases
Therapeutics
Pain

Keywords

  • pharmacology
  • skin signs of systemic disease
  • therapy-systemic

ASJC Scopus subject areas

  • Dermatology

Cite this

Livedoid vasculopathy and high levels of lipoprotein (a) : Response to danazol. / Criado, Paulo Ricardo; De Souza Espineli, Danielle Priscilia; Valentef, Neusayuriko Sakai; Alavi, Afsaneh; Kirsner, Robert.

In: Dermatologic Therapy, Vol. 28, No. 4, 01.07.2015, p. 248-253.

Research output: Contribution to journalArticle

Criado, PR, De Souza Espineli, DP, Valentef, NS, Alavi, A & Kirsner, R 2015, 'Livedoid vasculopathy and high levels of lipoprotein (a): Response to danazol', Dermatologic Therapy, vol. 28, no. 4, pp. 248-253. https://doi.org/10.1111/dth.12225
Criado, Paulo Ricardo ; De Souza Espineli, Danielle Priscilia ; Valentef, Neusayuriko Sakai ; Alavi, Afsaneh ; Kirsner, Robert. / Livedoid vasculopathy and high levels of lipoprotein (a) : Response to danazol. In: Dermatologic Therapy. 2015 ; Vol. 28, No. 4. pp. 248-253.
@article{dd5fc31fa47a49ca8c9fe2beeec935ce,
title = "Livedoid vasculopathy and high levels of lipoprotein (a): Response to danazol",
abstract = "Livedoid vasculopathy (LV) is a thrombo occlusive disorder presenting with recurrent painful ulcers of lower extremities. Association of LV with increased level of lipoprotein (a) (LP(a)), a risk factor for cardiovascular disease, has been reported. Danazol has been used with success in the management of LV, but none of the previous studies looked at the correlation between response to the treatment and level of LP(a). The aim of this study was to demonstrate the efficacy of low-dose danazol in the treatment of LV and its effects on LP(a). We present four cases with LV who were successfully treated with low-dose danazol, assessing the clinical characteristics and laboratory tests including the level of LP(a). The average age of the patients was 45 years and the mean duration of the disease was 19 years. The treatment regime of danazol 200 mg daily led to complete healing of ulcers and reduction in pain and a 70{\%} (ranging from 52 to 87{\%}) reduction in the level of LP(a). The limitation of this study is {"}small sample size.{"} In our patients with LV, low-dose danazol led to clinical improvement along with significant reduction in the level of LP(a).",
keywords = "pharmacology, skin signs of systemic disease, therapy-systemic",
author = "Criado, {Paulo Ricardo} and {De Souza Espineli}, {Danielle Priscilia} and Valentef, {Neusayuriko Sakai} and Afsaneh Alavi and Robert Kirsner",
year = "2015",
month = "7",
day = "1",
doi = "10.1111/dth.12225",
language = "English (US)",
volume = "28",
pages = "248--253",
journal = "Dermatologic Therapy",
issn = "1396-0296",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Livedoid vasculopathy and high levels of lipoprotein (a)

T2 - Response to danazol

AU - Criado, Paulo Ricardo

AU - De Souza Espineli, Danielle Priscilia

AU - Valentef, Neusayuriko Sakai

AU - Alavi, Afsaneh

AU - Kirsner, Robert

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Livedoid vasculopathy (LV) is a thrombo occlusive disorder presenting with recurrent painful ulcers of lower extremities. Association of LV with increased level of lipoprotein (a) (LP(a)), a risk factor for cardiovascular disease, has been reported. Danazol has been used with success in the management of LV, but none of the previous studies looked at the correlation between response to the treatment and level of LP(a). The aim of this study was to demonstrate the efficacy of low-dose danazol in the treatment of LV and its effects on LP(a). We present four cases with LV who were successfully treated with low-dose danazol, assessing the clinical characteristics and laboratory tests including the level of LP(a). The average age of the patients was 45 years and the mean duration of the disease was 19 years. The treatment regime of danazol 200 mg daily led to complete healing of ulcers and reduction in pain and a 70% (ranging from 52 to 87%) reduction in the level of LP(a). The limitation of this study is "small sample size." In our patients with LV, low-dose danazol led to clinical improvement along with significant reduction in the level of LP(a).

AB - Livedoid vasculopathy (LV) is a thrombo occlusive disorder presenting with recurrent painful ulcers of lower extremities. Association of LV with increased level of lipoprotein (a) (LP(a)), a risk factor for cardiovascular disease, has been reported. Danazol has been used with success in the management of LV, but none of the previous studies looked at the correlation between response to the treatment and level of LP(a). The aim of this study was to demonstrate the efficacy of low-dose danazol in the treatment of LV and its effects on LP(a). We present four cases with LV who were successfully treated with low-dose danazol, assessing the clinical characteristics and laboratory tests including the level of LP(a). The average age of the patients was 45 years and the mean duration of the disease was 19 years. The treatment regime of danazol 200 mg daily led to complete healing of ulcers and reduction in pain and a 70% (ranging from 52 to 87%) reduction in the level of LP(a). The limitation of this study is "small sample size." In our patients with LV, low-dose danazol led to clinical improvement along with significant reduction in the level of LP(a).

KW - pharmacology

KW - skin signs of systemic disease

KW - therapy-systemic

UR - http://www.scopus.com/inward/record.url?scp=84937705168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937705168&partnerID=8YFLogxK

U2 - 10.1111/dth.12225

DO - 10.1111/dth.12225

M3 - Article

VL - 28

SP - 248

EP - 253

JO - Dermatologic Therapy

JF - Dermatologic Therapy

SN - 1396-0296

IS - 4

ER -